Related Experiment Videos
The amyloid hypothesis: let sleeping dogmas lie?
Glenda M Bishop1, Stephen R Robinson
1Institute of Pathology, Case Western Reserve University, 2085 Adelbert Road, Cleveland, OH 44106, USA. gmb10@po.cwru.edu
Neurobiology of Aging
|December 10, 2002
Summary
The amyloid hypothesis for Alzheimer's disease (AD) faces challenges, as amyloid-beta (Abeta) may be neuroprotective. A new bioflocculant hypothesis suggests Abeta binds toxins for clearance, explaining trial outcomes.
Area of Science:
- Neuroscience
- Biochemistry
Background:
- The amyloid hypothesis has dominated Alzheimer's disease (AD) research for over a decade.
- This review critically examines data, particularly from transgenic mouse models, questioning the amyloid hypothesis's core tenets.
Discussion:
- Evidence suggests amyloid-beta (Abeta) peptide may possess neuroprotective properties, contrary to the amyloid hypothesis.
- The bioflocculant hypothesis is proposed, positing Abeta binds neurotoxic solutes for phagocytic removal.
Key Insights:
- Most data reviewed are inconsistent with the amyloid hypothesis's predictions.
- The bioflocculant hypothesis offers a falsifiable alternative, explaining Abeta's role in neuroprotection and toxin binding.
Outlook:
- The proposed bioflocculant hypothesis provides testable predictions for Alzheimer's disease research.
- This framework helps interpret recent negative outcomes in Abeta vaccination trials, prompting a reappraisal of AD pathogenesis.